Combination Therapy of TGF-β Blockade and Commensal-derived Probiotics Provides Enhanced Antitumor Immune Response and Tumor Suppression

Galunisertib (Gal) is a transforming growth factor (TGF-β) blockade which is being investigated as a potential tumor immunotherapy candidate drug in clinical trials. However, primary or acquired resistance is often found in the recruited cancer patients, which limits its clinical application. Tumor...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Linlin, Sheng, Jianyong, Wang, Mengli, Luo, Han, Zhu, Jun, Zhang, Bixiang, Liu, Zhi, Yang, Xiangliang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2019
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6592171/
https://www.ncbi.nlm.nih.gov/pubmed/31281535
http://dx.doi.org/10.7150/thno.35131

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6592171/
https://www.ncbi.nlm.nih.gov/pubmed/31281535
http://dx.doi.org/10.7150/thno.35131

Ejemplares similares